Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

TScan Therapeutics Inc

TCRX ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$0.78

▲ +0.88%

Market Cap $52.79M · Vol 29.41K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$52.79M

Micro Cap

Div Yield

N/A

EPS Growth

+10.45%

YoY

RSI (14)

52.17

Momentum

Beta

1.03

vs Market

52W High

$2.56

69.58% below

52W Low

$0.72

8.77% above

Volume

29.41K

Avg 94.13K

P/B

0.46

Price-to-book

ROE

-71.28%

Return on equity

Free Float

99.81%

Public shares

Shariah Compliance8 STANDARDS

✗ TScan Therapeutics Inc (TCRX) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does TCRX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-2.19%

-16.26%

-29.84%

-16.44%

YTD

-22.12%

-56.97%

-62.91%

-92.45%

Financials & Valuation

TTM · Annual

Total Revenue	$10.33M
Net Income	$-129,766,000.00
Revenue Growth (YoY)	-65.83%
Gross Margin	100.00%
Operating Margin	-1,296.01%
Net Profit Margin	-1,256.81%
ROE	-71.28%
ROA · ROIC	-43.26% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	12.57
P/B	0.46
P/FCF	N/A
EPS Growth	+10.45%
Outstanding Shares	67.78M

Technical Indicators

50-Day SMA	$0.90
200-Day SMA	$1.05
RSI (14)	52.17
Beta	1.03
52-Week High	$2.56
52-Week Low	$0.72

Volume Today	29.41K
Avg Daily Volume (30D)	94.13K
Relative Volume	0.31x
Volatility (10D)	44.82
Volatility (30D)	87.28
Free Float	99.81%

Analyst Consensus

BUY

Current Price $0.78

Mean Target $6.00

52W Low$0.72 52W High$2.56

Current

Target

$0.72 $2.56

Current Analyst target

+670.42% upside potential · 6 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00PH1N025

ISINUS89854M1018

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 12, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company's lead product candidate, TSC-101, is in development for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who are undergoing allogeneic hematopoietic cell transplantation (HCT). The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company builds a collection of therapeutic TCRs that recognize cancer-specific targets and are associated with multiple human leukocyte antigen (HLA) types, to provide customized multiplex TCR-T treatments for patients with a variety of solid tumors. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204.